Accelerating the development of
innovative discoveries into
life-changing biological medicines

 
 

The Selexis SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With global partners in 23 countries, 115 drug candidates in clinical development and four commercial products utilizing Selexis-generated cell lines, the Company empowers scientists and biopharmaceutical companies around the world to realize the full potential of their research.

115 clinical programs
4 marketed products
154 patents
9 key technology launches
 
100+ PD programs
100+ manufacturing batches
12+ INDs per year
1000+ analytical service projects

With more than 250 global partners, KBI’s broad range of product development services, expertise in biophysical and biochemical characterization of proteins, and flexible business model makes KBI a CDMO of choice. KBI's contract development and manufacturing services are built on a strategic cornerstone of deep analytical capabilities. We are passionate in the belief that detailed protein characterization drives speed, benefiting clients at every stage of the development and manufacturing process.

 
 

Reach the Clinic Faster

 

With GENE to GMP, we are committed to our partners' satisfaction. By predictably getting cGMP material for your clinical study, we help you concentrate on the other critical components of your development program.

 

Reach the
Clinic Faster

 

With GENE to GMP in 9 months, we are committed to our partners' satisfaction. By predictably getting cGMP material for your clinical study, we help you concentrate on the other critical components of your development program.

© Copyright 2019 GENE to GMP. All rights reserved.